Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03899649 · ClinicalTrials.gov registry record
A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer
A clinical trial of Stage III Pancreatic Cancer, sponsored by Angiodynamics.
- Active
- Registry status
- 532
- Enrollment target
- 14
- Study locations
NCT03899649: Active study of Stage III Pancreatic Cancer, sponsored by Angiodynamics.
NCT03899649 is a study of Stage III Pancreatic Cancer that is active but no longer recruiting, run by Angiodynamics. The registered enrollment target is 532 participants, above the 126-participant average among 13 other Stage III Pancreatic Cancer trials with a reported enrollment target (322% higher). The trial reports 14 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03899649, a study of Stage III Pancreatic Cancer, is active but no longer recruiting, sponsored by Angiodynamics.
- ACTIVE NOT RECRUITING
- Registry status
- 532 participants
- Enrollment target
- 14
- Study locations
Study Summary
This multicenter, observational study will evaluate the effectiveness and safety of the NanoKnife System when used for the ablation of Stage 3 pancreatic adenocarcinoma (Stage 3 PC). Eligible patients will be recruited over a 36-month period and participating institutions will enroll and provide data on consecutive patients that meet inclusion and exclusion criteria. Each patient will be followed up for the duration of the study or until death. The study will include two (2) cohorts: patients who received standard of care (SOC) and received irreversible electroporation (IRE) \[IRE cohort\], and patients who were treated with SOC and did not receive IRE \[SOC cohort\].
Primary Outcome
To evaluate the effectiveness of the NanoKnife System when used for the ablation of Stage 3 PC in real world treatment settings, by testing the hypothesis that IRE with the NanoKnife System improves overall survival (OS)
Conditions Studied
Interventions
- DEVICE NanoKnife System
- DRUG SOC
Study Locations (14)
Florida
- University of Florida Health - Gainesville
- Miami Cancer Institute - Miami
New York
- NYU Langone - New York
- Presbyterian Hospital, Columbia - New York
California
- Moores Cancer Center, UC San Diego Health - La Jolla
Georgia
- Wellstar Medical Group - Marietta
Illinois
- Northwest Community Hospital - Arlington Heights
Iowa
- University of Iowa Healthcare - Iowa City
Kentucky
- Norton Healthcare - Louisville
Minnesota
- Mayo Clinic, Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 532 participants |
| Start Date | 2019-05-08 |
| Est. Completion | 2025-04 |
What the registry record for NCT03899649 still lists
NCT03899649 is an observational study that tracks outcomes without assigning an intervention. The registered 532 participants enrollment target is mid-sized for trials with a published cap, above the 126-participant average among 13 other Stage III Pancreatic Cancer trials with a reported enrollment target (322% higher).
The record links to 1 condition, with Stage III Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which NanoKnife System is the first listed.
NCT03899649 lists 14 locations in 12 states (Florida, New York, California).
Frequently Asked Questions
What is clinical trial NCT03899649 about?
NCT03899649 is a clinical study titled "A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer". This multicenter, observational study will evaluate the effectiveness and safety of the NanoKnife System when used for the ablation of Stage 3 pancreatic adenocarcinoma (Stage 3 PC). Eligible patients will be recruited over a 36-month period and participating institutions will enroll and provide dat...
What is the current status of trial NCT03899649?
This trial is currently active not recruiting. The enrollment target is 532 participants. The study started on 2019-05-08. Estimated completion is 2025-04.
What conditions does trial NCT03899649 study?
This clinical trial studies the following conditions: Stage III Pancreatic Cancer.
What interventions are being tested in trial NCT03899649?
The interventions under investigation include: NanoKnife System (DEVICE), SOC (DRUG).
Who is sponsoring clinical trial NCT03899649?
This trial is sponsored by Angiodynamics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03899649 being conducted?
This trial has 14 study locations across California, Florida, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03899649's enrollment target sits among peer trials
532 2nd of 13 the highest of 13 other Stage III Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage III Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Malnutrition Screening and Dietary Intervention to Improve Nutrition Outcomes in Patients With Unresectable Pancreatic Cancer
ACTIVE NOT RECRUITING · NA
-
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05793151 · 532 participants · NA
Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
- NCT06378866 · 532 participants · Phase 2
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
- NCT07219173 · 531 participants · Phase 2
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI